Results of treatment with anticancer agents have steadily improved over the years following the introduction of more effective drugs and the establishment of better designed chemotherapy strategies. Still, chemotherapy failure due to cellular drug resistance remains a major problem in most cancer patients. Using cell lines made resistant to anticancer agents, several types of drug resistance have been characterised, among which are alterations in target proteins (Cabral et al., 1980; Flintoff & Essani, 1980) , carrier mediated drug uptake (Redwood & Colvin, 1980; Sirotnak et al., 1981) , cellular drug metabolism (Aronow et al., 1984) and cellular repair mechanisms (Bedford & Fox, 1982) . A very intriguing development in drug resistance research is the discovery of the phenomenon of multidrug resistance (MDR) (Bradley et al., 1988; van der Bliek & Borst, 1989) .
In MDR cells, selection for resistance to 'naturally occurring' drugs, e.g. anthracyclines, vinca alkaloids, podophyllotoxins, and colchicine, results in the development of cross-resistance to other members of the MDR drug family (Bech-Hansen et al., 1976; Dan0, 1972; Inaba & Johnson, 1977; Skovsgaard, 1978) . The MDR related drugs are structurally dissimilar and have different intracellular targets. What these drugs have in common is that they are lipophilic compounds derived from various natural products. In general, MDR cells are not cross-resistant to alkylating agents (e.g. chlorambucil and cyclophosphamide), antimetabolites (e.g. cytarabine, methotrexate, and 5-fluorouracil), or cisplatin.
A striking feature of the classical MDR phenotype is its reduced ability to accumulate drugs, as compared to the parent cell lines. This reduced drug accumulation is most likely the main cause of multidrug resistance (Dan0, 1973; Kessel & Bosmann, 1970; Riehm & Biedler, 1972; Sirotnak et al., 1986 , among other references). It is assumed that the reduced drug accumulation is due to activity of an energy dependent unidirectional drug efflux pump with broad substrate specificity. This drug pump is composed of a transmembrane glycoprotein (P-glycoprotein) with a molecular weight of 170 kD (Chen et al., 1986; Gerlach et al., 1986; Gros et al., 1986) . It uses energy in the form of ATP to transport drugs through a channel formed by the transmembrane segments (Hamada & Tsuruo, 1988; Horio et al., 1988) .
Different P-glycoprotein isoforms have been identified, and these are encoded by a family of closely related genes. They are referred to as pgp genes in hamsters and mdr genes in humans and mice (Ng et al., 1989) . In humans, two P-glycoprotein isoforms (mdrl and mdr3) with 80% amino acid homology have been identified (Roninson et al., 1986; van der Bliek et al., 1987) . By cross-hybridisation of human genomic DNA, Roninson and co-workers isolated two mdr specific genomic clones designated as mdrl and mdr2 (Roninson et al., 1986) . Independently, Borst and co-workers isolated mdr clones from cDNA libraries prepared from human liver tissue and the human liver cell line HepG2 (van der Bliek et al., 1987) . Sequences for two mdr genes were isolated. One corresponded to the previously reported human mdrl sequence (Chen et al., 1986) ; the other appeared to be the human homologue of the hamster pgp3 gene and was therefore called mdr3 (van der Bliek et al., 1987; van der Bliek et al., 1988a) . It is now known that the mdr3 gene of Borst et al. is identical in sequence to the mdr2 gene of Roninson et al. (Chin et al., 1989) . Both the human mdrl and mdr3 genes were found to be localised on the long arm of chromosome 7 (Callen et al., 1987) and to be linked within 330 kilobases (Chin et al., 1987) . Direct proof for the role of mdrl in MDR was obtained by transfection experiments. Expression of a full length cDNA clone of the human mdrl gene in a drug-sensitive cell conferred a complete MDR phenotype (Ueda et al., 1987) . However, the human mdr3 gene does not seem to be involved in drug resistance and no function of the gene product has yet been identified (van der Bliek et al., 1988a) .
Expression of the mdrl gene in normal tissues
Using slot blot analysis Fojo et al. (1987b) reported substantial expression of the human mdrl gene in normal adrenal, kidney, jejunal, rectal, liver and lung tissues. Other organs and tissues (skin, subcutaneous tissue, skeletal muscle, heart, spleen, bone marrow, lymphocytes, oesophagus, stomach, ovary, kidney cortex and spinal cord) had low or undetectable mdrl levels.
Expression was further studied at the cellular level by in situ hybridisation and immunohistochemical techniques (Cordon-Cardo et al., 1990; Thiebaut et al., 1987; van der Valk et al., 1990) . P-glycoprotein was mainly found in specialised epithelial cells with secretory or excretory functions. Thiebaut et al. (1987) used the monoclonal antibody MRK16, which is directed against an external epitope of the human P-glycoprotein (Hamada & Tsuruo, 1986) . In the liver, P-glycoprotein was found on the biliary surface of hepatocytes and small biliary ductules, in the pancreas on the luminal surface of the epithelial cells of small ductules and, in the kidney, on the brush border of the proximal tubules. The colon and jejunum both showed high levels of P-glycoprotein on the luminal surfaces of the mucosa. Cordon-Cardo et al. (1990) and van (Epstein et al., 1989; Ma et al., 1987; Rothenberg et al., 1989; Tsuruo et al., 1987; Weinstein et al., 1990 of the mdr expressing cells and the localisation of the mdr expressing cells in tumours. A tumour with a low percentage of cells expressing high levels of mdrl might give a low level of expression on average. Yet, such a small clone of high mdrl expressers may be sufficient to prevent effective chemotherapy in the patient.
The literature data on the detection of mdrl expression in solid tumours are summarised in Table I . Bulk techniques were used in all studies, except for those of Schneider et al. (1989 ), Salmon et al. (1989 and Chan et al. (1990) , in which immunohistochemistry was used. In most studies, the tumour samples were obtained from patients who had not received prior chemotherapy. In some, treatment status was not indicated (Fojo et al., 1987a; Gerlach et al., 1987; Lai et al., 1989; Moscow et al., 1989) and only a few compared both treated and untreated tumour samples (Bourhis et al., 1989a, b; Chan et al., 1990; Gerlach et al., 1987; Goldstein et al., 1989; Schneider et al., 1989) . We have arbitrarily divided the solid tumours into three expression groups. For tumours in all three groups, controversial reports on mdrl expression levels have been published, which to a great extent can be attributed to methodological differences, among others, the sensitivity of the applied assays. Therefore, we have placed the tumours in a specific group based on a general judgement and the selection of literature references in Tables I and II (Bell et al., 1985) . Two of five drug resistant ovarian tumours showed relatively high P-glycoprotein levels as quantified by Western blotting using the C219 monoclonal antibody directed against an internal epitope of the P-glycoprotein . However, later studies showed only low expression in three of a total of 88 ovarian tumours (Bourhis et al., 1989b; (Nooter et al., 1990a) . In vitro drug uptake studies showed that daunorubicin accumulation in PLL cells was increased by cyclosporin A Nooter et al., 1990a) . Since cyclosporins are inhibitors of the mdrl encoded P-glycoprotein drug pump, the suggestion is that mdr3 also can encode for a drug efflux pump in PLL cells. These data are in contradiction with the earlier mentioned transfection experiments and we cannot exclude the possibility that the presence of mdr3 mRNA and cyclosporin sensitive drug accumulation in PLL cells is merely coincidental. Further studies are needed to answer the question of whether mdr3 contributes to the primary resistance of (B-cell) leukaemias.
Intrinsic and acquired MDR phenotype
In tumours developed from tissues that normally have a substantial mdrl expression such as those of colon and kidneys, the mdrl expression is an inherent characteristic of the tumour cells. There are several observations that suggest that the MDR phenotype also can be acquired by tumours as a consequence of chemotherapy. For some tumour types, high mdrl expression levels are more frequently observed in treated tumours than in untreated ones. This has been found for acute myeloid leukaemias Herweijer et al., 1990; Holmes et al., 1989; Nooter et al., 1990b) , neuroblastomas (Bourhis et al., 1989a; Goldstein et al., 1990) and breast cancer (Schneider et al., 1989) . It is very likely that the acquisition of mdrl expression by the tumour occurs in the patient by selection of pre-existing mdrl expressing cells. However, there is increasing evidence that the mdrl promoter can be activated by chemical stress-inducing agents (Chin et al., 1990; Kohno et al., 1989) . Recently, it was found that exposure of a human renal adenocarcinoma cell line to sodium arsenite or cadmium chloride led to a 7-and 8-fold increase in mdrl mRNA and P-glycoprotien levels. This increase in P-glycoprotein correlated with a transient increase in resistance to vinblastine (Chin et al., 1990) . In another study, using an in vitro transient expression assay, it was found that the mdrl promoter could be activated directly by the addition of anticancer agents, including vincristine, daunorubicin and doxorubicin . These data suggest that chemotherapeutic agents might themselves directly cause the activation of the mdrl gene at the transcription level.
Can mdrl expression account for clinical drug resistace? Does the presence of mdrl expressing tumour cells limit successful chemotherapy? This of course, is the ultimate question. One of the strongest pieces of evidence that mdrl expression in vivo can induce acquired drug resistance, is provided by a transgenic mouse model (Galski et al., 1989) . Transgenic mice expressing the human mdrl gene in the haematopoietic tissues, appeared to be resistant to leukopenia induced by the anticancer agent daunomycin.
Expression levels of mdrl in human tumours can be as high as those of in vitro generated MDR cell lines (Dalton et al., 1989b; Fojo et al., 1987a; Goldstein et al., 1990; Herweijer et al., 1990; Kanamaru et al., 1989) . However, we do not know whether such levels of resistance (3-to 10-fold) can enable a tumour to survive the currently used chemotherapeutic treatment. Chemosensitivity studies with tumour biop-sies from breast cancer, myeloma and renal cell cancer have established inverse correlations between mdrl expression and in vitro sensitivity to MDR related drugs (Kakehi et al., 1988; Keith et al., 1990; Salmon et al., 1989) . However, for most drugs, we do not know the in vivo concentrations to which the tumour cells are exposed.
On the surface, there seems to be a fine correlation between the clinical manifestation of drug resistance and mdrl expression for a particular tumour type. Notorious inherent drug resistant tumours such as colon and renal cell cancers have the highest mdrl expression levels and tumours with low or undetectable mdrl levels such as Wilms' tumours respond much better to chemotherapy. However, this correlation is misleading and does not prove a contribution of mdrl in clinical drug resistance. Many intrinsic drug resistant tumours with high levels of mdrl expression also do not respond to other, MDR unrelated drugs. The MDR phenotype is most likely one of the many detoxification systems in these tumour cells (Moscow & Cowan, 1990) . For these tumours, the relative contribution of MDR to clinical drug resistance might be very small. However, recent evidence suggests that in some specific malignancies mdrl expression in the untreated tumour can indeed affect the outcome of subsequent chemotherapy. For neuroblastomas (Bourhis et al., 1989a) , acute myelocytic leukaemia (AML) (Sato et al., 1990 ) and soft tissue sarcomas (Chan et al., 1990) , high levels mdrl expression appeared to be associated with poor prognosis. Bourhis et al. (1989a) determined the clinical response of primary neuroblastomas to first-line chemotherapy including vincristine, doxorubicin and VP16. Two groups could be distinguished. In the first, all 15 patients with undetectable or low mdrl mRNA levels showed significant reduction in measurable disease. In the second group of 11 patients with high levels of mdrl expression, six showed significant reduction in measurable disease, two showed no response and in three disease progression occurred during the course of treatment. In AML, mdrl levels appeared to be most frequent in patients with the poorest response to chemotherapy (Sato et al., 1990) . Four of five patients in whom mdrl expression was minimal or absent showed complete remission, which lasted for relatively long periods of time. In contrast, seven of 10 patients whose leukaemic cells contained significant mdrl levels failed to show complete remission. In the other three patients, a complete remission was achieved only after prolonged chemotherapy.
A very impressive longitudinal study was published by Chan et al. who observed a highly significant correlation between P-glycoprotein expression and the clinical outcome of drug treatment in soft tissue sarcomas in childhood (Chan et al., 1990) . Chan et al. (1990) markedly improved an immunohistochemical technique for P-glycoprotein detection that can even be applied to formalin fixed, paraffin embedded tissue sections. In nine of 29 soft tissue sarcomas, small patches of P-glycoprotein positive cells were detected. These would probably have been missed in using bulk techniques and they appeared to be of crucial importance in the development of drug resistance. All nine patients with Pglycoprotein positive tumours relapsed after MDR related chemotherapy, as compared with only one in 20 with Pglycoprotein negative tumours. Even low levels of P-glycoprotein expression comparable with 8-fold relative resistance to vincristine in vitro were finally associated with clinically significant drug resistance. As the disease progressed, the number of P-glycoprotein positive cells and the expression levels in individual cells increased. (Tsuruo et al., 1981) . As of now, a large number of such so-called resistance modifying agents (RMAs) has been found including: other calcium antagonists, e.g. diltiazem, nicardipine, niludipine (Tsuruo et al., 1985) ; phenothiazines (Ford et al., 1989) ; indole alkaloids, e.g. reserpine and reserpine analogs (Pearce et al., 1989) as well as other alkaloids and amines (Zamora et al., 1988) ; analogs of triparanol, e.g. tamoxifen (Ramu et al., 1984) , dipyridamole (Ramu & Ramu, 1989) , and dihydropyridine (Nogae et al., 1989) and cyclosporins (Nooter et al., 1989; Slater et al., 1986; Twentyman, 1988) . For a number of these substances, structure/ activity relationship studies have indicated physical and chemical features necessary to modulate MDR Ford et al., 1989; Pearce et al., 1989; Ramu & Ramu, 1989) . In most cases, the reversal of resistance by RMAs is accompanied by increased accumulation of cytotoxic agents by the resistant cells as determined by radiolabelled drugs, fluorescence microscopy or laser flow cytometry (Hofsli & Nissen-Meyer, 1990; Kessel & Wilberding, 1985; Krishan et al., 1986; Nooter et al., 1989; Tsuruo et al., 1984; Tsuruo et al., 1982; Willingham et al., 1986; Yalowich & Ross, 1985) .
The current hypothesis on the mode of action of RMAs is that they correct the defective cytotoxic drug accumulation by competing for outward transport directly through an interaction, i.e., binding with P-glycoprotein (Akiyama et al., 1988; Cornwell et al., 1987; Foxwell et al., 1989; Naito & Tsuruo, 1989; Safa, 1988 (Ozols et al., 1987) and with vinblastine and VP-16 in pediatric drug resistant tumours (Cairo et al., 1989) . Verapamil was also used in combination with tamoxifen and doxorubicin, vincristine plus etoposide as the initial chemotherapy in small cell lung cancer (Figueredo et al., 1990) . The combination of trifluoperazine and doxorubicin was given for a variety of refractory malignancies (Miller et al., 1988) . In colon and renal cancer, cyclosporin A was combined with epidoxorubicin and vinblastine, respectively (Verweij et al., 1990) . Epidoxorubicin was also given in combination with quinidine as first line chemotherapy in advanced breast cancer (Jones et al., 1990) . These investigations, which were primarily intended as feasibility studies, have shown that there is no dramatic increased toxicity for normal tissues such as renal, hepatic, or intestinal epithelia with high levels of P-glycoprotein. There was also no evidence that RMAs potentiated the acute toxicities of the cytotoxic drugs. The clinical efficacy of the experimental protocols was assessed by the occurrence of otherwise unexpected tumour responses and the results overall are disappointing. A shortcoming of the above mentioned studies is a lack of data on P-glycoprotein expression in the tumours, making an evaluation difficult. More suitable for future studies would seem to be the haematological malignancies, because of the possibility of repeated tumour sampling.
Promising results have been obtained in two studies, one in multiple myeloma (Dalton et al., 1989a) and another in acute myelocytic leukaemia . Verapamil was added to the standard regimen of vincristine, doxorubicin and dexamethasone (VAD) in patients with refractory multiple myeloma (7) or non-Hodgkin's lymphoma
(1) (Dalton et al., 1989a) . Objective clinical responses were observed in three of eight patients who previously had been refractory to vincristine and doxorubicin. Six of these eight patients had evidence of P-glycoprotein expression in their tumour cells; of these, two showed a partial response and one gave a complete response for 6 months. However, three of six P-glycoprotein positive patients did not show objective response with the combined VAD + verapamil treatment.
From a therapeutic point of view, important features of MDR cells are their reduced drug accumulation and the resulting reduced drug sensitivity, which can both be restored by RMAs. We have shown that, in leukaemic cells expressing mdrl, the steady-state accumulation of daunorubicin could be significantly increased by cyclosporin A or verapamil Nooter et al., 1990b) . Since these RMAs inhibit the mdrl encoded drug pump, our data suggest that this pump is functional in leukaemias expressing the mdrl gene. We recently reported treatment of a refractory AML patient with daunorubicin and cytarabine combined with cyclosporin A . In that case, the emergence of the MDR phenotype was monitored during clinical progression of the disease. At relapse, a decrease in daunorubicin accumulation by AML blasts was associated with elevated mdrl expression and a decreased in vitro sensitivity to daunorubicin. Intracellular daunorubicin accumulation and in vitro sensitivity could be completely restored by adding cyclosporin A to the cells. During progressive relapse, the patient was treated with reinduction therapy to which cyclosporin A was added and this resulted in elimination of the mdrl positive AML clone. After 12 weeks, the resistant mdrl expressing clone reappeared in the blood and bone marrow.
In our opinion, future studies along this line in haematological malignancies should preferably include the following:
(a) RMAs are added to the cytotoxic protocols as early as possible in the development of clinical drug resistance; and, (b) the efficacy of the currently used protocols, and those to which RMAs are added, in killing mdrl expressing tumour cells in relationship to the level of mdrl expression are monitored by in situ methods. Since mdrl is also frequently expressed in untreated haematological malignancies, combination therapy should also be considered in previously untreated patients.
Another point of consideration is that the pharmacokinetics and, as a consequent of that the toxicity and efficacy of cytotoxic drugs, might be influenced by the simultaneous use of RMAs (Bright & Buss, 1990; Fedeli et al., 1989; Kerr et al., 1986; Nooter et al., 1987) . Therefore, we strongly recommend animal studies in which pharmacokinetics, optimal schedules and toxicology of combined drugs can be determined.
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